Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375160 | 0.96 | HSP90AB1 (0.42) | HSP90AB1ACHECA12CA1CA2 | |
| SCHEMBL11717012 | 0.89 | PGK1 (0.48) | HSP90AB1ACHECA12CA1CA2 | |
| SCHEMBL11707522 | 0.81 | GABRA1 (0.46) | CYP3A4CALM1GABRA1GABRG2GABRB3 | |
| SCHEMBL9464672 | 0.80 | PGK1 (0.38) | CA1CA2PTGS2PGK1PGK2 | |
| SCHEMBL10253270 | 0.79 | CALM1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27531399 | 0.79 | PTPN1 (0.37) | PTPN1PTGS2PGK1PGK2CYP3A4 | |
| SCHEMBL15375122 | 0.77 | PGK1 (0.57) | PGK1PGK2CYP3A4TDP1 | |
| SCHEMBL3396258 | 0.76 | EGFR (0.43) | HSP90AB1CA12CA1CA2CA7 | |
| SCHEMBL21429710 | 0.76 | HSP90AB1 (0.40) | HSP90AB1ACHEPTPN1PTGS2CYP3A4 | |
| SCHEMBL911756 | 0.76 | MEN1 (0.56) | CA1CA2CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | HSP90AB1 1068/4885ACHE 893/4885CA12 4757/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | HSP90AB1 1068/4885ACHE 871/4885CA12 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.